NCT04138043View on ClinicalTrials.gov

Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of GSK2330811 in Healthy Japanese Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 5, 2019

Primary Completion Date

May 28, 2020

Study Completion Date

May 28, 2020

Conditions

Healthy Volunteers

Interventions

DRUG

Placebo

Placebo is 0.9 percent sodium chloride solution. It will be administered as SC injection to abdomen by study personnel. Three injections will be used to match active doses.

DRUG

GSK2330811

GSK2330811 will be available as SC injection 150 mg/mL.

Trial Locations (1)

NW10 7EW

GSK Investigational Site, London